Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia
Beijing, China, December 9, 2021/PRNewswire/ – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial…
Read more
2021 Highlights: Humanized Model Publications
We are proud to highlight our growing list of publications featuring off-the-shelf and customized mouse, rat, and cancer cell models in well-respected, high-impact journals. Featured below…
Read more
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase I Clinical Trial of YH004 (Anti-4-1BB Monoclonal Antibody) in Australia
BEIJING, CHINA, December 7, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of…
Read more
Biocytogen/Eucure Biopharma’s YH001 (Anti-CTLA-4 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration
BEIJING, November 9, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…
Read more
Webinar: Investigating Inflammatory Disease using Humanized Cytokine Mice
Our webinar “Investigating Inflammatory Disease using Humanized Cytokine Mice” was live on Dec 1, 2021 at 1PM. In this webinar, we will: - Review the…
Read more
Biocytogen/Eucure Biopharma’s YH003 (Anti-CD40 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration
BEIJING, November 2, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…
Read more
Eucure Biopharma, a Subsidiary of Biocytogen, and TRACON Pharmaceuticals Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001
YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions YH001 is currently being dosed in multiple Phase 1 oncology trials…
Read more
Biocytogen Announces Collaboration With Envigo To Distribute the B-NDG Triple Immunodeficient and Humanizable Mouse Model
BEIJING and BOSTON, Sept. 28, 2021 /PRNewswire/ -- Biocytogen announces a collaboration with Envigo, a global organization offering the broadest range of research models and related services. The two companies…
Read more
Webinar: Advancing T cell Therapies Using B-hCD3 Mouse Models
We are pleased to launch a new webinar series! Our webinar “Advancing T cell Therapies Using B-hCD3 Mouse Models” was live on Oct 28 at…
Read more
Team Building in the White Mountains
July 27, 2021 - Biocytogen Boston Corporation held a team-building retreat at the Grand View Mountain Resort in New Hampshire last week. The event, propelled…
Read more